TCSAM
AVIR icon

Tyrus Capital S.A.M.’s Atea Pharmaceuticals AVIR Stock Holding History

Tyrus Capital S.A.M.’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$3.78M Hold
1,260,000
– – 35.9% 1
2023
Q2 		$4.71M Hold
1,260,000
– – 33.11% 1
2023
Q1 		$4.22M Hold
1,260,000
– – 24.86% 1
2022
Q4 		$6.06M Buy
+1,260,000
New +$6.37M 13.2% 2

Other funds holding AVIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Tyrus Capital S.A.M.'s AVIR Position: Q3 2023 in Review

Tyrus Capital S.A.M. held its Atea Pharmaceuticals (AVIR) position steady in Q3 2023 at 1,260,000 shares worth $3.78M. The position accounts for 35.9% of the portfolio, ranked #1.

Tyrus Capital S.A.M. first reported a position in AVIR in Q4 2022 and has held it in 4 quarters since. The position peaked at $6.06M in Q4 2022. 119 funds tracked by Wall St. Rank hold AVIR as of Q3 2023.

  • Tyrus Capital S.A.M. held 1,260,000 shares of Atea Pharmaceuticals worth $3.78M as of Q3 2023.
  • Tyrus Capital S.A.M. left its Atea Pharmaceuticals share count unchanged in Q3 2023.
  • Atea Pharmaceuticals made up 35.9% of Tyrus Capital S.A.M.'s portfolio in Q3 2023, its #1 holding.
  • Tyrus Capital S.A.M. first reported a position in Atea Pharmaceuticals in Q4 2022 and has held it in 4 quarters since.
  • Tyrus Capital S.A.M.'s Atea Pharmaceuticals position peaked at $6.06M in Q4 2022.
  • 119 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q3 2023.

Based on Tyrus Capital S.A.M.'s 13F filing for Q3 2023, filed 14 Nov 2023.